Scarica l'app Stockscreener
4.00
3.63%
0.14
Dopo l'orario di chiusura:
3.93
-0.07
-1.75%
Precedente Chiudi:
$3.86
Aprire:
$3.86
Volume 24 ore:
1.31M
Relative Volume:
0.61
Capitalizzazione di mercato:
$385.17M
Reddito:
-
Utile/perdita netta:
$-81.49M
Rapporto P/E:
-4.9444
EPS:
-0.809
Flusso di cassa netto:
$-73.48M
1 W Prestazione:
-5.88%
1M Prestazione:
+21.21%
6M Prestazione:
+122.22%
1 anno Prestazione:
-9.09%
Intervallo 1D:
$3.86
$4.2295
Intervallo di 1 settimana:
$3.705
$4.37
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.00 | 385.17M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
RZLT stock on the move: What sparks the 38% jump in the past week? - MSN
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL) - The Globe and Mail
Positive Signs As Multiple Insiders Buy Rezolute Stock - Yahoo Finance
RZLT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Cautious OutlookDiluted EPS Report - newsline.com
Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT) - The Globe and Mail
REZOLUTE INC (RZLT) Stock Chart - ChartMill
RZLT: Strong interim efficacy in tumor HI and key regulatory milestones expected later this year - TradingView
RZLT: Strong interim efficacy in tumor HI and regulatory clarity for congenital HI expected this year - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - The Globe and Mail
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society - The Manila Times
Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism - Quiver Quantitative
Rezolute (RZLT) Receives a Buy from Guggenheim - The Globe and Mail
Phase 3 congenital hyperinsulinism study results to be shared at ENDO 2026 - Stock Titan
RZLT Maintained by Maxim Group -- Price Target Raised to $14.00 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Rezolute (RZLT) Gains on Upgrade Following Positive Trial Data - GuruFocus
Rezolute upgraded at Citizens after late-stage trial data for lead asset - Seeking Alpha
RZLT Maintained by Wedbush -- Price Target Raised to $6.00 - GuruFocus
RZLT Upgraded by Citizens -- Price Target Announced at $11.00 - GuruFocus
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute’s stock up on interim Phase III tumour HI data - Yahoo Finance
Cantor Fitzgerald reiterates Neutral on Rezolute stock on trial data - Investing.com
Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating - marketscreener.com
Rezolute Price Target Raised to $6.00/Share From $5.00 by BTIG - Moomoo
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $14 - Moomoo
Rezolute (RZLT) Shares Rise on Positive Trial Update for Ersodet - GuruFocus
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study - Benzinga
RZLT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Rezolute rises after late-stage trial update (RZLT:NASDAQ) - Seeking Alpha
Rezolute Announces Positive Interim Phase 3 upLIFT Results for Ersodetug in Tumor Hyperinsulinism, Six of Eight Responders Achieved IV Glucose Discontinuation 1 - Minichart
Rezolute (RZLT) Shares Phase 3 Study Progress of Ersodetug in Tu - GuruFocus
Rezolute reports interim data from tumor hyperinsulinism trial By Investing.com - Investing.com South Africa
Rezolute Reports Positive Phase 3 Data for Ersodetug - TipRanks
Rezolute reports interim data from tumor hyperinsulinism trial - Investing.com
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism - The Manila Times
Rezolute interim Phase 3 upLIFT data: 6 of 8 meet primary responder criterion; study 50% enrolled - TradingView
Rezolute (NASDAQ: RZLT) reports positive Phase 3 upLIFT tumor HI data - Stock Titan
Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial - marketscreener.com
Rezolute (RZLT) Q1 2026 Earnings: EPS Surpasses Estimates Amid Continued R&D ProgressEstimate Accuracy - The Legal Advocate
RZLT Q1 2026 Earnings: EPS Beat Expectations Despite Negative Stock ReactionEarnings Weakness Phase - newsline.com
Rezolute (RZLT) Edges Higher: Key Levels to Watch After 1.08% GainOutside Reversal - newsline.com
RZLT Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Pipeline AdvancesEarnings Momentum Score - newsline.com
Rezolute Inc. (RZLT) Slides Amid Sector Pressure: Key Levels to WatchBPI Reversal - newsline.com
RZLT Stock Price, Quote & Chart | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Opaleye Management Inc. Increases Stake in Rezolute Inc. - GuruFocus
Balyasny holds 5,048,421 shares of Rezolute (NASDAQ: RZLT), ~5.28% stake - Stock Titan
RZLT Maintains by Maxim Group -- Price Target Raised to $10.00 - GuruFocus
FDA review puts Rezolute's genetic disorder drug path in question - MSN
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):